CommercialNovember 1, 2021
Nevada specialty pharmacy updates (MAC)
Effective for dates of service on and after February 1, 2022, the following specialty pharmacy codes from current and new clinical criteria documents will be included in our prior authorization (PA) review process.
Please note that the inclusion of a National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.
Clinical Criteria is available here.
Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by the medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health® (AIM), a separate company.
Clinical Criteria |
Drug |
HCPCS or CPT Code |
ING-CC-0096* |
Rylaze(asparaginase erwinia chrysanthemi (recombinant)-rywn) |
J3590 |
ING-CC-0167* |
Ruxience |
Q5119 |
ING-CC-0167* |
Truxima |
Q5115 |
ING-CC-0202 |
Saphnelo (anifrolumab-fnia) |
J3490, J3590 |
ING-CC-0203 |
Ryplazim (plasminogen, human-tvmh) |
J3490, J3590 |
*Oncology use is managed by AIM
Step therapy updates
Effective for dates of service on and after February 1, 2022, the following specialty pharmacy codes from current and new clinical criteria documents will be included in our existing specialty pharmacy medical step therapy review process.
Clinical Criteria |
Status |
Drug |
HCPCS or CPT Code(s) |
ING-CC-0075 |
Preferred |
Rituxan |
J9312 |
Riabni |
Q5123 |
||
Non-preferred |
Ruxience |
Q5119 |
|
Truxima |
Q5115 |
||
ING-CC-0167*
|
Preferred (no PA or step therapy required) |
Rituxan |
J9312 |
Riabni |
Q5123 |
||
Non-preferred |
Ruxience |
Q5119 |
|
Truxima |
Q5115 |
*Oncology use is managed by AIM
Quantity limit updates
Effective for dates of service on and after February 1, 2022, the following specialty pharmacy codes from current and new clinical criteria documents will be included in our quantity limit review process.
Clinical Criteria |
Drug |
HCPCS or CPT Code |
ING-CC-0081 |
Crysvita (burosumab-twza) |
J0584 |
ING-CC-0202 |
Saphnelo (anifrolumab-fnia) |
J3490, J3590 |
PUBLICATIONS: November 2021 Anthem Provider News - Nevada
To view this article online:
Visit https://providernews.anthem.com/nevada/articles/nevada-specialty-pharmacy-updates-mac-9065
Or scan this QR code with your phone